Veyfortus Special Drug use result surveillance

Veyfortus Special Drug use result surveillance (surveillance targeted neonates, infants, and young children at risk of serious RSV infection who received Beyfortus) - Veyfortus Special Drug use result surveillance

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057699

Enrollment

1000

Registered

2025-04-24

Start date

2025-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

RSV infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Neonates, infants or children (up to 24 months) who are vulnerable to severe RSV-related disease and are at the early stage of epidemic in the 1st or 2nd RSV season, among patients eligible for the indication of Beyfortus as per routine clinical practice.

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
- Incidence of Beyfortus "serious hypersensitivity" and "thrombocytopenia" through 150 days post dose - Incidence of MA RSV LRTI through 150 days post dose	—

Countries

Japan

Contacts

Public ContactPublic contact for Drug use surveillance

Medical Affairs Post-authorization regulatory studies

Sanofi_Medical@sanofi.com03-6301-3867

Outcome results